Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 30
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-1.55%
|
$118,699
$217.21 P/Share
|
|
Apr 27
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,884
-3.01%
|
$838,944
$216.65 P/Share
|
|
Apr 27
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Exercise of conversion of derivative security
|
Direct |
3,884
+8.11%
|
$334,024
$86.52 P/Share
|
|
Apr 05
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,686
-2.27%
|
$360,804
$214.44 P/Share
|
|
Apr 01
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,344
-3.46%
|
$287,616
$214.16 P/Share
|
|
Mar 05
2021
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,141
-7.64%
|
$1,074,469
$209.99 P/Share
|
|
Mar 01
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,782
-5.98%
|
$587,002
$211.8 P/Share
|
|
Feb 26
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,218
-14.9%
|
$470,216
$212.42 P/Share
|
|
Feb 25
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,028
-2.13%
|
$644,964
$213.79 P/Share
|
|
Feb 25
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
3,634
-1.4%
|
$774,042
$214.0 P/Share
|
|
Feb 25
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
3,028
-2.31%
|
$644,964
$213.79 P/Share
|
|
Feb 25
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,586
-1.69%
|
$767,404
$214.25 P/Share
|
|
Feb 25
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,080
-1.73%
|
$230,040
$213.87 P/Share
|
|
Feb 24
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,416
-6.19%
|
$524,272
$217.57 P/Share
|
|
Feb 24
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,898
-6.08%
|
$628,866
$217.57 P/Share
|
|
Feb 24
2021
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.93%
|
$67,487
$217.57 P/Share
|
|
Feb 24
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,898
-4.36%
|
$628,866
$217.57 P/Share
|
|
Feb 24
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,416
-6.66%
|
$524,272
$217.57 P/Share
|
|
Feb 24
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,946
-6.31%
|
$639,282
$217.57 P/Share
|
|
Feb 24
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
864
-5.13%
|
$187,488
$217.57 P/Share
|
|
Feb 24
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-3.19%
|
$224,812
$217.57 P/Share
|
|
Feb 24
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-1.53%
|
$118,699
$217.57 P/Share
|
|
Feb 18
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,825
-4.4%
|
$1,651,075
$211.95 P/Share
|
|
Feb 18
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
7,825
-3.69%
|
$1,651,075
$211.89 P/Share
|
|
Feb 18
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
7,825
-4.68%
|
$1,651,075
$211.98 P/Share
|
|
Feb 18
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
9,264
-4.35%
|
$1,954,704
$211.63 P/Share
|
|
Feb 18
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,295
-7.23%
|
$906,245
$211.5 P/Share
|
|
Feb 17
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-11.75%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-10.11%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,080
-3.03%
|
$438,880
$211.75 P/Share
|
|
Feb 17
2021
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,970
-21.95%
|
$2,947,670
$211.75 P/Share
|
|
Feb 17
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-12.39%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
7,613
-11.98%
|
$1,606,343
$211.75 P/Share
|
|
Feb 17
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,740
-11.48%
|
$578,140
$211.75 P/Share
|
|
Feb 17
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,000
-5.8%
|
$422,000
$211.75 P/Share
|
|
Feb 11
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,283
-4.56%
|
$1,114,713
$211.04 P/Share
|
|
Feb 11
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,156
-2.6%
|
$1,087,916
$211.23 P/Share
|
|
Feb 11
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
4,318
-2.66%
|
$911,098
$211.2 P/Share
|
|
Feb 11
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
4,460
-2.2%
|
$941,060
$211.21 P/Share
|
|
Feb 11
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,686
-2.09%
|
$354,060
$210.93 P/Share
|
|
Feb 11
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,498
-2.98%
|
$314,580
$210.89 P/Share
|
|
Feb 10
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,974
-4.85%
|
$636,436
$214.16 P/Share
|
|
Feb 10
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,101
-4.43%
|
$663,614
$214.16 P/Share
|
|
Feb 10
2021
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,367
-6.59%
|
$506,538
$214.16 P/Share
|
|
Feb 10
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,962
-4.14%
|
$633,868
$214.16 P/Share
|
|
Feb 10
2021
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,954
-17.98%
|
$2,986,156
$214.16 P/Share
|
|
Feb 10
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,563
-4.48%
|
$548,482
$214.16 P/Share
|
|
Feb 10
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,421
-3.44%
|
$518,094
$214.16 P/Share
|
|
Feb 10
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,344
-3.21%
|
$287,616
$214.16 P/Share
|
|
Feb 10
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
651
-2.5%
|
$139,314
$214.16 P/Share
|